Bicara Therapeutics Inc. 8-K

What Happened Bicara Therapeutics Inc. filed a Form 8‑K on May 21, 2026 (Item 8.01) to announce a press release reporting three‑year overall survival and deep responses for ficerafusp alfa combined with pembrolizumab in first‑line recurrent/metastatic (1L R/M) HPV‑negative head and neck squamous cell carcinoma (HNSCC). The press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 21, 2026; Item reported: 8.01 Other Events.
• Program: ficerafusp alfa plus pembrolizumab in 1L R/M HPV‑negative HNSCC.
• Claim in release: "Differentiated three‑year overall survival and deep responses driven by TGF‑β inhibition."
• Press release included as Exhibit 99.1 in the 8‑K; report signed by CEO Claire Mazumdar, Ph.D.

Why It Matters This 8‑K is a clinical update rather than a financial report or management change. For investors, the communicated three‑year overall survival and deep response findings are material clinical data points for Bicara’s development program and may be relevant to future regulatory, partnership, or development milestones. The filing makes the company’s clinical claims publicly available via the attached press release; investors should review the full release and subsequent company disclosures for detailed data and context.